Can we predict psoriasis relapse after biologics? a new study digs into the clues.

NCT ID NCT07730619

Ongoing Knowledge-focused Sponsor: First Affiliated Hospital Xi'an Jiaotong University Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study investigates why some people with plaque psoriasis experience a relapse after treatment with biologic drugs, while others do not. Researchers will compare patients who relapsed with those who did not, looking at factors like age, lifestyle, lab results, and treatment history. The goal is to identify warning signs and evaluate which follow-up treatments work best after a relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: biologic agents (e.g., adalimumab) for plaque psoriasis
What this could lead to: If successful, this could help doctors predict which psoriasis patients are likely to relapse after biologic therapy and choose the best next treatment.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients or biologics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOLOGIC AGENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOLOGIC AGENTS INFLUENCE FACTORS PLAQUE PSORIASIS RELAPSE

Contacts and locations

Locations

Dermatology Department of the First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710061, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.